Cummins-Meritor Regional Brake Training Events Return in 2024
COLUMBUS, Ind.–(BUSINESS WIRE)–#cummins—Cummins-Meritor®, a leading provider of integrated drivetrain solutions, today announced the return of... Read more.
Frontier Announces Fiber Securitization Offering
DALLAS–(BUSINESS WIRE)–Frontier Communications Parent, Inc. (NASDAQ: FYBR) (“Frontier” or the “Company”) today announced that a limited-purpose,... Read more.
OneWater Marine Inc. Responds to Market Reports
BUFORD, Ga.–(BUSINESS WIRE)–OneWater Marine Inc. (NASDAQ: ONEW) (“OneWater” or the “Company”) today released the following statement in response... Read more.
Acrisure Commences Tender Offer and Consent Solicitation
GRAND RAPIDS, Mich.–(BUSINESS WIRE)–Acrisure, LLC, a Michigan limited liability company (“Acrisure” or the “Company”), announced today that it... Read more.
Gorman-Rupp Completes Debt Refinancing
MANSFIELD, Ohio–(BUSINESS WIRE)–#refinancing–The Gorman-Rupp Company (NYSE: GRC) (the “Company”), a leading designer, manufacturer, and international... Read more.
Wesley Ramjeet to Join Lobe Sciences’ Board of Directors, Bringing Decades of Strategic Financial Expertise
Accomplished Investor and Serial Entrepreneur VANCOUVER, British Columbia–(BUSINESS WIRE)–Lobe Sciences Ltd. (OTCQB: LOBEF) (CSE: LOBE) (“Lobe”... Read more.
Devonian Appoints André P. Boulet to Chairman of the Board and Chief Operating Officer
MONTREAL–(BUSINESS WIRE)–Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXV: GSD; OTCQB: DVHGF), a clinical stage botanical pharmaceutical... Read more.
Acrisure Announces Proposed Notes Offering
GRAND RAPIDS, Mich.–(BUSINESS WIRE)–Acrisure, LLC (the “Company”) and Acrisure Finance, Inc. (together with the Company, the “Issuers”) announced... Read more.
Arrowhead Pharmaceuticals Reports Successful Topline Results for Plozasiran from the Pivotal Phase 3 PALISADE Study in Patients with Familial Chylomicronemia Syndrome
– Plozasiran achieved statistically significant median reductions in triglycerides up to 80% and mean reductions in APOC3 up to 94% at month 10 – Plozasiran... Read more.
Neurogene Announces NGN-401 Gene Therapy for Rett Syndrome Selected by FDA for START Pilot Program
NGN-401 is one of only three CBER programs chosen by FDA NGN-401 was selected based on potential for clinical benefits and clinical development program readiness... Read more.